Financial Results - Quarter Ended 30 September 2026
Income Statement Highlights
Revenue from operations: ₹1,119.83 million (Q2 FY27) vs ₹1,018.48 million (Q2 FY26) - 9.9% YoY increase
Other income: ₹29.04 million (Q2 FY27) vs ₹26.58 million (Q2 FY26)
Total Income: ₹1,148.87 million (Q2 FY27) vs ₹1,045.06 million (Q2 FY26)
Employee benefits expense: ₹306.67 million (Q2 FY27) vs ₹286.13 million (Q2 FY26)
Depreciation & amortization: ₹128.68 million (Q2 FY27) vs ₹102.40 million (Q2 FY26)
Profit before tax: ₹275.25 million (Q2 FY27) vs ₹262.74 million (Q2 FY26)
Tax expense: ₹69.11 million (Q2 FY27) vs ₹63.54 million (Q2 FY26)
Net profit: ₹206.14 million (Q2 FY27) vs ₹199.20 million (Q2 FY26) - 3.5% YoY increase
Basic EPS: ₹4.61 (Q2 FY27) vs ₹4.46 (Q2 FY26)
Diluted EPS: ₹4.57 (Q2 FY27) vs ₹4.44 (Q2 FY26)
Half Year Ended 30 September 2026
Revenue from operations: ₹2,210.57 million (H1 FY27) vs ₹1,994.12 million (H1 FY26)
Net profit: ₹416.56 million (H1 FY27) vs ₹388.13 million (H1 FY26)
Basic EPS: ₹9.32 (H1 FY27) vs ₹8.71 (H1 FY26)
Diluted EPS: ₹9.23 (H1 FY27) vs ₹8.65 (H1 FY26)
Capital Structure
Paid-up equity share capital: ₹89.40 million as of 30 September 2026 (face value ₹2 per share)
Other equity: ₹4,479.39 million as of 31 March 2026
Corporate Developments
Subsidiary Incorporation: The Board noted the incorporation of Vimta Labs LLC as a wholly-owned subsidiary in the USA, following earlier intimation dated 6 May 2026.
ESOP Grants: The Nomination and Remunerations Committee granted 14,000 stock options to eligible employees under Vimta Labs Employee Stock Option Plan 2021 (VLESOP-2021) on 26 October 2026.
Employee compensation expense related to stock options: ₹9.43 million for Q2 FY27, ₹8.46 million for Q1 FY27, and ₹16.62 million for Q2 FY26.
Operational Highlights
Segment Information: The company has only one reportable segment - 'Contract Research and Testing Services'.
PPP Agreement: The company has a Public Private Partnership agreement with FSSAI dated 29 June 2021 to setup, operate and transfer a National Food Testing Laboratory in JNPT, Mumbai, treated as a Service Concessionaire Arrangement under Ind AS 115.
Lab setup revenue and costs: ₹0.00 million for Q2 FY27, ₹0.45 million for Q1 FY27, ₹0.13 million for Q2 FY25, and ₹1.20 million for FY26.
Balance Sheet Highlights (as of 30 September 2026)
Total assets: Approximately ₹5,485.67 million (sum of non-current and current assets)
Property, plant and equipment: ₹234.41 million
Trade receivables: ₹1,192.65 million
Cash and cash equivalents: ₹373.30 million
Bank balances: ₹327.82 million
Total equity: Approximately ₹4,568.79 million (share capital + other equity)
Cash Flow Highlights (Half Year Ended 30 September 2026)
Cash from operating activities: ₹459.37 million
Cash used in investing activities: ₹(333.85) million
Cash from/(used in) financing activities: ₹18.05 million
Net increase in cash: ₹143.57 million
Exceptional Items
The company recognized an exceptional item of ₹16.16 million for the year ended 31 March 2026 related to the statutory impact of new Labour Codes effective from 21 November 2025, primarily from revision in the definition of wages for gratuity.
Governance
Managing Director: Harita Vasireddi (DIN: 00242512)
Company Secretary & Compliance Officer: Sujani Vasireddi
